Page loading, please wait...
Antibiotics and antimicrobial therapy
ÒÀÁËÅÒÊΠANTIBIOTIC.ru
Hello, guest! :: Today: Monday, April 22, 2019 Russian page Russian 
 Main page :: IAC :: ISPR :: SCMAR :: IACMAC :: CMAC
Site navigation

WHO

Clinical Microbiology and Antimicrobial Chemotherapy - Official IACMAC Journal
Conferences, Seminars and Workshops

IACMAC activity plan for 2018-2019

  • VII South-Russian Conference on Antimicrobial Therapy (March 28–29, 2019, Krasnodar)
  • XXI International Congress “Antimicrobial Therapy” (May 22–24, 2019, Moscow)
  • Russian-Chinese Congress on Antimicrobial Therapy and Clinical Microbiology (October 17–18, 2019, Ufa)

Online course “Antimicrobial Stewardship: Managing Antibiotic Resistance”

You are invited to participate in Massive Open Online Course (MOOC) in Russian. This educational course was developed by Dundee University, the British Society for Antimicrobial Chemotherapy (BSAC) and the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC).

IACMAC Educational Program

The National educational program “Diagnostics, treatment and prevention of infectious diseases caused by multidrug resistant microorganisms”

Nosocomial infectious diseases (2 session)

  • 27.04.2019 — Event Hall «ALMAZ», Profsoyuznaya street, Kirov
  • 18.05.2019 — Novotel Hotel, 7, Engels street, Ekaterinburg
 

Community-acquired infectious diseases (3 session)

  • 20.04.2019 — Osnabryuk Hotel, 20, Saltykov-Schedryn street, Tver
  • 27.04.2019 — Open City Hotel, 2, Syuyumbike prospect, Naberezhnye Chelny

Dear Colleagues! Due to certain technical issues and obstacles the list of cities participating in the National educational program “Diagnostics, treatment and prevention of infectious diseases caused by multidrug resistant microorganisms. Nosocomial infectious diseases” was shortened.

Studies

Dear colleagues! We encourage to take part in multicenter prospective microbiological study of the antimicrobial resistance of community-acquired pathogens: S. pneumoniae, H. influenzae and S. pyogenes (PeGAS study).

Since 2015 IAC and IACMAC have conducted multicenter study aimed to evaluate the prevalence of mutation resistance to macrolide antibiotic in Mycoplasma pneumonia and Mycoplasma genitalium.

Website News

European Committee on Antimicrobial Susceptibility Testing (EUCAST) has amended the clinical classification of susceptibility (categories S,I and R): currently the clinical evaluation of susceptibility is connected with drug exposure in the nidus of infection.

The occupational standard on specialty "Medical microbiology" from the Ministry of Healthcare of the Russian Federation is posted on IACMAC website.

Clinical Microbiology and Antimicrobial Chemotherapy vol. 20, №3 is posted on the website.

Clinical guidelines on diagnostics and treatment of community-acquired pneumonia in adults.

The Russian Respiratory Society (RRC) and the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC) have published for discussion the clinical guidelines on diagnostics and treatment of community-acquired pneumonia in adults.

Clinical guidelines “Mucoviscidosis: microbiological diagnostics of chronic respiratory infection”

Clinical guidelines on antimicrobial susceptibility testing, approved at the IACMAC extended session in Moscow are posted on the website.

Clinical guidelines on isolation, identification and antimicrobial susceptibility of Helicobacter pylori are added.

New Articles
Site News

Effectiveness of honey dressing in the treatment of diabetic foot ulcers: A systematic review and meta-analysis

Honey dressing has been applied in the treatment of diabetic foot ulcers (DFUs). However, there is a lack of research showing ample evidence that honey dressing is more effective in the treatment of DFUs than other dressings. This study aimed to examine the effects of honey dressing on wound-healing process for DFUs.
Mar 20, 2019 - 10:15
Read more... :: Reads: 606
Site News

Eravacycline: A review in complicated intra-abdominal infections

Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired resistance mechanisms.
Mar 18, 2019 - 10:15
Read more... :: Reads: 589
Site News

Use and safety of azithromycin in neonates: a systematic review

Azithromycin significantly reduces the risk of BPD in preterm neonates. The relationship between azithromycin and IHPS requires further investigation.
Mar 06, 2019 - 10:20
Read more... :: Reads: 598
Site News

Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial

Addition of S. boulardii to sequential therapy improved H. pylori eradication rate and reduced the incidence of treatment-associated AEs in Moroccan patients with H. pylori infection.
Mar 05, 2019 - 10:15
Read more... :: Reads: 560
Site News

Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial

Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation Against Pneumonia (LEAP 1) study (NCT02559310) was a global noninferiority trial to evaluate the efficacy and safety of lefamulin for the treatment of CABP.
Mar 01, 2019 - 13:40
Read more... :: Reads: 542
Site News

Analysis of infectious spondylodiscitis: 7-years data

Infectious spondylodiscitis is an infectious disease that is rare and difficult to diagnose due to its non-specific clinical features. In this study, we aimed to describe the clinical and diagnostic features of infectious spondylodiscitis.
Feb 28, 2019 - 14:20
Read more... :: Reads: 539
Site News

FDA to review Merck agents against cUTIs, cIAIs, nosocomial pneumonia

According to Merck, the agency accepted an NDA for priority review for a combination of relebactam, an investigational beta-lactamase inhibitor, with imipenem/cilastatin (MK-7655A, IMI/REL) for the treatment of complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) caused by certain susceptible gram-negative bacteria for adults who have limited or no alternative therapies.
Feb 25, 2019 - 00:53
Read more... :: Reads: 521
Site News

Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells

“Strep throat” is highly prevalent among children, yet it is unknown why only some children develop recurrent tonsillitis (RT), a common indication for tonsillectomy. To gain insights into this classic childhood disease, we performed phenotypic, genotypic, and functional studies on pediatric group A Streptococcus (GAS) RT and non-RT tonsils from two independent cohorts.
Feb 14, 2019 - 14:20
Read more... :: Reads: 528
Site News

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994

Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the FDA of its Investigational New Drug (IND) application for SPR994, Spero’s lead product candidate designed to be the first oral carbapenem antibiotic, for the treatment of complicated urinary tract infections (cUTI).
Feb 12, 2019 - 11:45
Read more... :: Reads: 531
Site News

Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials

Randomised controlled trials (RCTs) of vitamin D to prevent COPD exacerbations have yielded conflicting results. Individual participant data meta-analysis could identify factors that explain this variation.
Jan 28, 2019 - 14:10
Read more... :: Reads: 553
Next »

Institute of Antimicrobial Chemotherapy (IAC) Scientific Center of Monitoring Antimicrobial Resistance The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy Department of Clinical Pharmacology
© 2000-2019 IAC SSMA  website@antibiotic.ru